STUDY THE EFFECT OF CONJUGATED NOVEL ULTRASHORT ANTIMICROBIAL PEPTIDES IN COMBINATION WITH FARNESYL AGAINST RESISTANCE STRAINS OF PSEUDOMONAS AERUGINOSA
DOI:
https://doi.org/10.22159/ijap.2026v18i1.55076Keywords:
Pseudomonas aeruginosa, Antimicrobial peptides (AMPs), Multi-drug-resistant, Antibiotics, Bacterial activityAbstract
Objective: The objective of this study was to design and evaluate a novel ultrashort antimicrobial peptide, San-112003, structurally conjugated with a farnesyl chain, for its potential antibacterial activity against both antibiotic-susceptible and multi-drug-resistant (MDR) strains of Pseudomonas aeruginosa. Given the rising threat of antimicrobial resistance and the limitations of conventional antibiotics, antimicrobial peptides (AMPs) are explored as a promising alternative. This study aimed to assess the efficacy, toxicity, and potential synergism of San-112003 with conventional antibiotics.
Methods: In this study, we designed and synthesized a novel ultrashort antimicrobial peptide, San-112003, which incorporates repeating tripeptide units (tryptophan–arginine–glycine) chemically conjugated to a farnesyl chain. This structural design enhances membrane targeting and antimicrobial potency. The antimicrobial efficacy of San-112003 was evaluated against both antibiotic-susceptible and MDR strains of P. aeruginosa. Hemolytic toxicity assays were conducted on human red blood cells, and synergy studies were performed in combination with conventional antibiotics, including gentamicin.
Results: San-112003 was successfully synthesized with 99% purity and correct molecular mass confirmation. The peptide showed low cytotoxicity in MTT assays across tested concentrations. It demonstrated potent bactericidal activity against Pseudomonas aeruginosa, with MIC and MBC values of 0.5 µg/ml for the control strain and 2.5 µg/ml for the MDR strain. Hemolysis testing indicated minimal toxicity at concentrations relevant to antimicrobial activity. Synergy testing revealed the greatest enhancement in bacterial inhibition when combined with gentamicin, with FICI values of 0.075 for the control strain and 0.20 for the MDR strain. Additionally, the peptide–antibiotic combinations reduced bacterial biofilm viability more effectively than the peptide alone.
Conclusion: San-112003 is a promising AMP–farnesyl conjugate with potent activity against P. aeruginosa, including MDR strains. Its synergism with gentamicin and low hemolytic toxicity suggest that AMP–antibiotic combinations could serve as a valuable strategy against antibiotic resistance.
References
1. Yin R, Cheng J, Wang J, Li P, Lin J. Treatment of Pseudomonas aeruginosa infectious biofilms: challenges and strategies. Front Microbiol. 2022;13:955286. doi: 10.3389/fmicb.2022.955286, PMID 36090087.
2. Dolan SK. Current knowledge and future directions in developing strategies to combat Pseudomonas aeruginosa infection. J Mol Biol. 2020;432(20):5509-28. doi: 10.1016/j.jmb.2020.07.021, PMID 32750389.
3. Langendonk RF, Neill DR, Fothergill JL. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies. Front Cell Infect Microbiol. 2021;11:665759. doi: 10.3389/fcimb.2021.665759, PMID 33937104.
4. Klubthawee N, Adisakwattana P, Hanpithakpong W, Somsri S, Aunpad R. A novel rationally designed hybrid antimicrobial peptide inspired by cathelicidin and aurein exhibits membrane active mechanisms against Pseudomonas aeruginosa. Sci Rep. 2020;10(1):9117. doi: 10.1038/s41598-020-65688-5, PMID 32499514.
5. Masihzadeh S, Amin M, Farshadzadeh Z. In vitro and in vivo antibiofilm activity of the synthetic antimicrobial peptide WLBU2 against multiple drug resistant Pseudomonas aeruginosa strains. BMC Microbiol. 2023;23(1):131. doi: 10.1186/s12866-023-02886-x, PMID 37183241.
6. Yin Q, Wu S, Wu L, Wang Z, Mu Y, Zhang R. A novel in silico antimicrobial peptide DP7 combats MDR Pseudomonas aeruginosa and related biofilm infections. J Antimicrob Chemother. 2020;75(11):3248-59. doi: 10.1093/jac/dkaa308, PMID 32737484.
7. Jahangiri A, Neshani A, Mirhosseini SA, Ghazvini K, Zare H, Sedighian H. Synergistic effect of two antimicrobial peptides nisin and P10 with conventional antibiotics against extensively drug-resistant acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates. Microb Pathog. 2021;150:104700. doi: 10.1016/j.micpath.2020.104700, PMID 33346078.
8. Bussmann RW, Sharon D. Plantas medicinales de los Andes y la Amazonia la flora magica y medicinal del norte del peru. Ethnobot Res Appl. 2018;15(1):1-293. doi: 10.32859/era.15.1.001-293.
9. Grumaz C, Hoffmann A, Vainshtein Y, Kopp M, Grumaz S, Stevens P. Rapid next-generation sequencing-based diagnostics of bacteremia in septic patients. J Mol Diagn. 2020;22(3):405-18. doi: 10.1016/j.jmoldx.2019.12.006, PMID 32146977.
10. Almaaytah A, Qaoud MT, Abualhaijaa A, Al Balas Q, Alzoubi KH. Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides. Infect Drug Resist. 2018 Jun 1;11:835-47. doi: 10.2147/IDR.S166236, PMID 29910626.
11. Birteksoz Tan AS, Zeybek Z, Hacioglu M, Savage PB, Bozkurt Guzel C. In vitro activities of antimicrobial peptides and ceragenins against Legionella pneumophila. J Antibiot (Tokyo). 2019;72(5):291-7. doi: 10.1038/s41429-019-0148-1, PMID 30755738.
12. Lee YC, Chen PY, Wang JT, Chang SC. A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains. BMC Pharmacol Toxicol. 2019;20(1):25. doi: 10.1186/s40360-019-0305-y, PMID 31060599.
13. Kowalska Krochmal B, Dudek Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation clinical relevance. Pathogens. 2021;10(2):165. doi: 10.3390/pathogens10020165, PMID 33557078.
14. Patil SV, Hajare AL, Patankar M, Krishnaprasad K. In vitro fractional inhibitory concentration (FIC) study of cefixime and azithromycin fixed-dose combination (FDC) against respiratory clinical isolates. J Clin Diagn Res. 2015;9(2):DC13-5. doi: 10.7860/jcdr/2015/12092.5560, PMID 25859454.
15. Bidaud AL, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the assessment of in vitro and in vivo antifungal combinations. J Fungi (Basel). 2021;7(2):113. doi: 10.3390/jof7020113, PMID 33557026.
16. Oh R, Lee MJ, Kim YO, Nam BH, Kong HJ, Kim JW. Myticusin beta antimicrobial peptide from the marine bivalve Mytilus coruscus. Fish Shellfish Immunol. 2020;99:342-52. doi: 10.1016/j.fsi.2020.02.020, PMID 32061872.
17. Yasir M, Dutta D, Willcox MD. Activity of antimicrobial peptides and ciprofloxacin against Pseudomonas aeruginosa biofilms. Molecules. 2020;25(17):3843. doi: 10.3390/molecules25173843, PMID 32847059.
18. Kim H, Jang JH, Kim SC, Cho JH. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa. Eur J Med Chem. 2020;185:111814. doi: 10.1016/j.ejmech.2019.111814, PMID 31678742.
19. Martins AF, Rabinowitz P. The impact of antimicrobial resistance in the environment on public health. Future Microbiol. 2020;15(9):699-702. doi: 10.2217/fmb-2019-0331, PMID 32530297.
20. Xu SJ, Chen JH, Chang S, Li HL. The role of miRNAs in T helper cell development activation fate decisions and tumor immunity. Front Immunol. 2024;14:1320305. doi: 10.3389/fimmu.2023.1320305, PMID 38264670.
21. Zharkova MS, Orlov DS, Golubeva OY, Chakchir OB, Eliseev IE, Grinchuk TM. Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics a novel way to combat antibiotic resistance. Front Cell Infect Microbiol. 2019;9:128. doi: 10.3389/fcimb.2019.00128, PMID 31114762.
22. Han X, Kou Z, Jiang F, Sun X, Shang D. Interactions of designed Trp-containing antimicrobial peptides with DNA of multidrug-resistant Pseudomonas aeruginosa. DNA Cell Biol. 2021;40(2):414-24. doi: 10.1089/dna.2019.4874, PMID 32023094.
23. Wang K, Wang J, Li L, Xu L, Feng N, Wang. Synthesis of a novel anti-freezing non-drying antibacterial hydrogel dressing by one pot method. Chem Eng J. 2019;372:216-25. doi: 10.1016/j.cej.2019.04.107.
24. Aiemsaard J, Singh R, Borlace GN, Sripanidkulchai B, Tabboon P, Thongkham E. Antibacterial activity of cannabis extract (Cannabis sativa L. subsp. Indica (Lam.)) against canine skin infection bacterium Staphylococcus pseudintermedius. Scienceasia. 2022;48(3):348. doi: 10.2306/scienceasia1513-1874.2022.053.
25. Yasir M, Willcox MD, Dutta D. Action of antimicrobial peptides against bacterial biofilms. Materials (Basel). 2018;11(12):2468. doi: 10.3390/ma11122468, PMID 30563067.
26. Porto WF, Irazazabal L, Alves ES, Ribeiro SM, Matos CO, Pires AS. In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design. Nat Commun. 2018;9(1):1490. doi: 10.1038/s41467-018-03746-3, PMID 29662055.
27. Patrulea V, Gan BH, Perron K, Cai X, Abdel Sayed P, Sublet E. Synergistic effects of antimicrobial peptide dendrimer-chitosan polymer conjugates against Pseudomonas aeruginosa. Carbohydr Polym. 2022;280:119025. doi: 10.1016/j.carbpol.2021.119025, PMID 35027127.
28. Huang F, Cai X, Hou X, Zhang Y, Liu J, Yang L. A dynamic covalent polymeric antimicrobial for conquering drug-resistant bacterial infection. Exploration (Beijing). 2022;2(5):20210145. doi: 10.1002/exp.20210145, PMID 37325499.
29. Parducho KR, Beadell B, Ybarra TK, Bush M, Escalera E, Trejos AT. The antimicrobial peptide human beta-defensin 2 inhibits biofilm production of Pseudomonas aeruginosa without compromising metabolic activity. Front Immunol. 2020;11:805. doi: 10.3389/fimmu.2020.00805, PMID 32457749.
30. Han X, Zheng J, Lin F, Kuroda K, Chen Z. Interactions between surface-immobilized antimicrobial peptides and model bacterial cell membranes. Langmuir. 2017;34(1):512-20. doi: 10.1021/acs.langmuir.7b03411, PMID 29232144.
Published
How to Cite
Issue
Section
Copyright (c) 2026 ALI SALAMA, SANDRELLA MOHAMMED SAIF
This work is licensed under a Creative Commons Attribution 4.0 International License.